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Tumornecrosisfactor-a(TNF-a)hasimportantrolesinseveralimmunologicaleventsbyregulatingapoptosisandtranscriptional
activation of cytokine genes. Intracellular signaling mediated by TNF-receptor-type 1 (TNFR1) is constituted by two sequential
protein complexes: Complex-I containing the receptor and Complex-II-containing Caspase-8. Protein modiﬁcations, particularly
ubiquitination, are associated with the regulation of the formation of these complexes. However, the underlying mechanisms
remain poorly deﬁned. Here, we identiﬁed CLIP-170-related 59kDa protein (CLIPR-59) as a novel adaptor protein for TNFR1.
Experimental reduction of CLIPR-59 levels prevented induction of apoptosis and activation of caspases in the context of TNF-a
signaling. CLIPR-59 binds TNFR1 but dissociates in response to TNF-a stimulation. However, CLIPR-59 is also involved in and
needed for the formation of Complex-II. Moreover, CLIPR-59 regulates TNF-a-induced ubiquitination of receptor-interacting
protein 1 (RIP1) by its association with CYLD, a de-ubiquitinating enzyme. These ﬁndings suggest that CLIPR-59 modulates
ubiquitination of RIP1, resulting in the formation of Complex-II and thus promoting Caspase-8 activation to induce apoptosis by
TNF-a.
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Induction of apoptosis mediated by tumor necrosis factor (TNF)
family cytokines has important roles in several immunological
processes by killing cells infected with pathogens, eliminating
tumor cells and terminating immune responses.
1–6 Members of
the death receptor (DR) family, which include TNF-receptor-
type 1 (TNFR1), Fas, TRAMP/DR3, TRAILR1/DR4, TRAILR2/
DR5 and DR6, are capable of inducing apoptosis in response to
stimulation by their speciﬁc ligands, which induce higher-order
aggregation of DR molecules in the plasma membrane, leading
to recruitment of several intracellular proteins to the cytoplasmic
domains of these receptors.
4,7
Recently, it was demonstrated that the intracellular signal-
ing mediated by TNFR1 is constituted by formation of
two sequential protein complexes.
8,9 Aggregation of TNFR1
mediated by its speciﬁc ligand induces the recruitment of
adaptor proteins TNF receptor-associated death domain
protein (TRADD) and receptor-interacting protein 1 (RIP1) to
the cytoplasmic domain of TNFR1 (Complex-I). Subse-
quently, these proteins dissociate from Complex-I, facilitating
the formation of a second protein complex (Complex-II)-
containing Fas-associated protein with death domain (FADD)
and Caspase-8, which is an initiator of the proteolytic cascade
resulting in apoptosis.
4,10,11 In addition, it is reported that the
transitionfromComplex-ItoComplex-IIisregulatedbyprotein
modiﬁcations, particularly ubiquitination of RIP1.
12–14
Early (o30min) after TNF-a stimulation, RIP1 is conju-
gated with at least two types ubiquitin chains, K63- and
K48-linked.
15 Whereas K-48-dependent ubiquitinated RIP1
is degradated by proteasome-dependent mechanisms,
K63-dependent ubiquitinated RIP1 functions as a scaffold
that assembles signaling complexes that activate kinases
responsible for gene expression pathways.
16 Later (460min),
RIP1 is de-ubiquitinated and enters into Complex-II.
8,14,15
A recent study using a site-speciﬁc mutant of RIP1, showed
that abolishing ubiquitination of RIP1 facilitates its involvement
in Complex-II.
12 These results suggest that de-ubiquitination
of RIP1 regulates the formation of Complex-II in apoptotic
signaling by TNF-a.
Results
CLIP-170-related 59kDa protein (CLIPR-59) involves in
TNFR1-containing Complex-I. Recently, we identiﬁed
CLIPR-59 as a novel interacting protein for the cytoplasmic
tail of DR6 by yeast two hybrid (Y2H) screening using
human fetal brain cDNA library.
17 Here, we determined
the interaction of CLIPR-59 with other DRs by Y2H assay
(Figure 1a). Positive results were detected for DR6 and
TNFR1 but not other members of the DR family.
Independently, co-immunoprecipitation (co-IP) assays using
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www.nature.com/cddisFigure1 InteractionofCLIPR-59withDR.(a)YeaststrainAH109wastransformedwithcombinationofexpressionplasmids.Cellswereselectedbyprototrophyforleucin,
tryptophan,histidineandadenine.ThecombinationofpGBKT7-p53andpGADT7-largeTantigenwasusedaspositivecontrol.(bandc)HEK293Tcellsweretransfectedwith
theindicatedcombinationsofexpressionplasmids.TRADDinteractionwithDR3wasincludedaspositivecontrols.At17h aftertransfection, cellswerelysedandsubjectedto
IP with the indicated Ab and analyzed by IB. (e) HEK293T cells were transfected with the expression plasmids for FLAG-tagged WT, deletion mutants, del 234 (D234–358
amino acid) or del DD (D359–438 amino acid) of TNFR1, schematically shown in (d) and HA-tagged CLIPR-59, and analyzed as described in (b). (f) HeLa cells, transfected
with control (N) or CLIPR-59-speciﬁc siRNA(C) were stimulated with TNF-a (100ng/ml) in the presence of CHX (10mg/ml) during the indicated period. Cells were lysed and
immunoprecipitatedwithanti-TNFR1antibody(Ab)orcontrolIgG(shownas ).Theimmunoprecipitatedproteinswereanalyzedasdescribedin(b).(h)NIH3T3cells(1 10
8
cells) were transfected with expression plasmids encoding hCD40-hDR6 chimeric protein, which schematically shown in (g), and HA-tagged CLIPR-59. At 17h after
transfection,cellswereincubatedforvarioustimeswith agonisticanti-human CD40Ab(cloneG28-5).Afterincubation,cellswerelysed,andhCD40-hDR6 complexligatedby
clone G28-5 was immunoprecipitated with protein G sepharose. For the sample at 0 time point, clone G28-5(þ) or non-speciﬁc IgG( ) was added in the cell lysate of non-
stimulated cells transfected with hCD40-hDR6 and CLIPR-59, before adding protein G sepharose. Samples were analyzed by IB
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Cell Death and Diseaselysates from cells transfected with plasmids encoding DR
family proteins conﬁrmed that CLIPR-59 interacts with
TNFR1 (Figure 1b) but not DR3 (Figure 1c). In the case of
the interaction of DR6 with CLIPR-59, the membrane
proximal region of DR6 was previously found to be
essential for this interaction.
17 In co-IP assay using various
deletion mutants for TNFR1, del 234, lacking the membrane
proximal region (234–358 amino acid) or del death domain
(DD), lacking the DD (359–438 amino acid; Figure 1d), we
observed that the membrane proximal region of TNFR1 is
also essential for interaction with CLIPR-59 (Figure 1e).
The formation of active TNFR1-containing protein complex
(Complex-I) is regulated by receptor aggregation.
8 Therefore,
we examined the effect of the ligand stimulation on the
association of TNFR1 with CLIPR-59. In HeLa cells, co-IP
assays using anti-TNFR1-speciﬁc antibody (Ab) showed that
CLIPR-59 was associated with TNFR1 before ligand stimula-
tion and this association was signiﬁcantly reduced at 120min
after stimulation (Figure 1f). Complex-II formation is reported
to be induced 4120min after TNFR1 stimulation.
8 Similar
results were obtained using a receptor cross-linking assay
using a human CD40-speciﬁc agonistic Ab with a chimeric
CD40/DR6 receptor protein, which consists of the extra-
cellular domain of human CD40 and the transmembrane
and cytoplasmic regions of DR6 (Figures 1g and h).
CLIPR-59 is essential for the induction of apoptosis in
TNF-a signaling. We examined the role of CLIPR-59 in
apoptosis induced by TNF-a. Effects of RNAi-mediated
knockdown of CLIPR-59 (Supplementary Figure S1) on
apoptosis stimulated by TNF-a were assessed by apoptotic
morphological changes and by a cell viability assay. HeLa
cells transfected with siCLIPR-59 or control siNS were
stimulated with TNF-a in the presence of cycloheximide
(CHX). Cells transfected with control siNS exhibited typical
apoptotic morphological changes (cytoplasmic blebbing and
cell shrinking) in response to TNF-a with CHX, but not with
CHX alone or with medium alone (Figure 2a). Interestingly, in
contrast to these observations, treatment with siCLIPR-59
markedly reduced the number of cells exhibiting these
apoptotic morphological changes (Figure 2a). Cell viability
assays also showed that treatment with siCLIPR-59 protects
cells against cytotoxicity induced by TNF-a (Figure 2b and
Supplementary Figure S2), but not by cytotoxic chemical
reagents, such as puromycin (Figure 2c), which is a protein
synthesis inhibitor, nor zeocin (Figure 2d), which is a member
of the bleomycin family of antibiotics and causes cell death
by intercalating into and cleaving DNA. In contrast to
CLIPR-59 knockdown, overexpression of CLIPR-59 enhanced
apoptosis induced by TNF-a alone or TNF-a plus CHX
(Figure 2e). In addition, deleting the region of TNFR1
required for CLIPR-59 binding abolished its ability to
promote caspase activation, showing that the recruitment
of CLIPR-59 into TNFR1 complex is required for TNF-a-
mediated apoptosis induction, in addition to TNFR1’s DD
(Figures 2f and 1d, e). Furthermore, by Caspase-Glo assay
using a luminogenic Caspase-3/7 substrate, which contains
the tetrapeptide sequence DEVD (Caspase-3/7 Glo reagent,
Promega, Madison, WI, USA), it was shown that treatment
with siCLIPR-59 markedly reduced the activation of effector
caspases induced by TNF-a plus CHX compared with control
siNS treatment (Figure 2g). The same data were obtained by
the assay using siRNAs (siCLIPR-59-2 and siCLIPR-59-3)
targeting different regions within CLIPR-59 mRNA (Figure 2g).
Altogether, these ﬁndings suggest that CLIPR-59 contributes
to the induction of apoptosis by TNF-a.
CLIPR-59 regulates the activation of Caspase-8 in TNF-a
signaling. We also evaluated the role of CLIPR-59 in
TNF-a-induced activation of Caspase-8, an upstream
initiator caspase that is recruited to Complex II. HeLa cells
treated with siNS or siCLIPR-59 were stimulated with TNF-a
plus CHX, then Caspase-8 activity was measured 3h later by
luminogenic substrate, Z-IETD-aminoluciferin (Caspase-8
Glo reagent, Promega). Treatment with siCLIPR-59
markedly reduced Caspase-8 activity induced by TNF-a
plus CHX, compared with siNS treatment (Figure 3a). By
immunoblot assay using anti-Caspase-8-speciﬁc Ab, we also
observed that CLIPR-59 is required for TNF-a-induced
Caspase-8 processing (Figure 3b). These ﬁndings
suggested that CLIPR-59 participates in the activation of
Caspase-8 in TNF-a signaling.
In previous report, CLIPR-59 was associated with Akt
activation in the context of adipocyte differentiation.
18 In
addition, some reports have suggested that Akt has anti-
apoptotic role by directly phosphorylating the pro-apoptotic
protein BAD at position Ser 136. Thus, we tested the effect of
CLIPR-59 knockdown on Akt-mediated phosphorylation of
BAD in the setting of TNF-a signaling (Supplementary Figure
S3A). In this assay, we did not observe a role for CLIPR-59 in
regulating phosphorylation of this Akt substrate during TNF-a
signaling. In addition, siCLIPR-59 did not affect apoptosis
induced by overexpression of either Caspase-8 or BAD
(Supplementary Figure S3B). Taken together, our ﬁndings
suggest that CLIPR-59 operates upstream of Caspase-8 in
TNF-a signaling.
CLIPR-59 regulates the formation of Complex-II-
containing Caspase-8. Several adaptor proteins, such as
FADD, TRADD and RIP1, regulate the activation of
Caspase-8 during TNFR1 signaling,
4,7,11,14 prompting us
to hypothesize that CLIPR-59 might exert its inﬂuences
by these adaptor proteins. We ﬁrst examined the association
of CLIPR-59 with adaptor proteins by co-IP assay using
plasmid-transfected cells. These experiments provided
evidence that CLIPR-59 associates with complexes
containing FADD and Caspase-8, but not TRADD
(Figure 3c). Another adaptor protein RIP1 was also
immunoprecipitated with CLIPR-59 (Figure 3d). Moreover,
based on Y2H assays, the interaction of CLIPR-59 with RIP1
but not Caspase-8 or FADD, appears to be direct (Figure 3e).
These ﬁndings thus suggested that CLIPR-59 could be
involved in the protein complex containing Caspase-8, FADD
and RIP1, which is known as Complex II. To evaluate these
protein interactions in the context of TNF-a signaling, co-IP
assays using anti-Caspase-8-speciﬁc Ab were performed,
showing that CLIPR-59 was co-precipitated with Caspase-8
and revealing that this interaction was enhanced by TNF-a
stimulation (Figure 3f). Moreover, CLIPR-59 knockdown
disrupted the interaction of Caspase-8 with both FADD and
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Cell Death and DiseaseFigure 2 CLIPR-59 contributes to TNF-a-mediated pro-apoptotic signaling. (a) HeLa cells transfected with siCLIPR-59 or siNS were stimulated with medium alone,
(CHX,10mg/ml)orTNF-a(10ng/ml)withCHX(10mg/ml).At6hafterstimulation,morphologicalchangeswereobservedbylightmicroscopy.HeLacellstransfectedwithsiNS
orsiCLIPR-59werestimulatedwithvariousamountsofTNF-ainthepresenceofCHX(10mg/ml;b),orchemicalcytotoxicdrug,puromycin(c)orzeocin(d).At6h(inthecase
forTNF-a),24h(forpuromycin)or48h(forzeocin)afterstimulation,cellviabilitywasassessedbyWSTassay(errorbarmeans±S.D.;n¼3).(e)HeLacells,transfectedwiththe
plasmid for expressing GFP-tagged CLIPR-59 or GFP alone, were stimulated with TNF-a (the indicated concentration, ng/ml) with or without CHX (10mg/ml). At 24h after
stimulation, the percentage of cell death of the transfected cells was assessed as described in Materials and Methods (error bar means±S.D.; n¼3). (f) HeLa cells were
transfected with the indicated expression vector plasmids. At 24h after transfection, cell-viability, IETDase or DEVDase activity of these cells were assessed by WST assay,
Caspase-8 or Caspase-3/7 Glo reagents (Promega) measuring relative ﬂuorescent units (RFU), respectively, (error bar means±S.D.; n¼3). (g) HeLa cells transfected with
the indicated siRNAs directed to three different target sites on CLIPR-59 mRNA were stimulated with TNF-a (10ng/ml) with or without CHX (10mg/ml). At 4.5h after
stimulation, DEVDase activity was assessed as described in (f) (error bar means±S.D.; n¼3). To determine the effects of siRNA treatment on the protein and mRNA
expression level of CLIPR-59 were assessed by western blot using the indicated Abs and RT-PCR using primers speciﬁc for CLIPR-59 or GAPDH (lower panel), respectively
Figure 3 CLIPR-59 promotes the activation of Caspase-8 by regulating the formation of Complex-II in TNF-a signaling. (a) HeLa cells treated with the indicated siRNAs
were stimulated by TNF-a (10ng/ml) plus CHX(10mg/ml). At 3h after stimulation, Caspase-8 activity was measured as described in Figure 2f. Data are mean±S.D.;
n¼3.(b)HeLacellstransfectedwith siNSorsiCLIPR-59werestimulatedwithTNF-a(10ng/ml)plusCHX(10mg/ml)fortheindicatedperiods.Cellswerelysedandanalyzed
byIB usingthe indicatedAbs.(c andd) HEK293Tcells weretransfectedwith theindicatedcombinationof expression plasmids.At 24h aftertransfection,cells wereanalyzed
as described in Figure 1b. (e) Yeast two-hybrid assays using the combination of plasmids for the indicated genes were performed as described in Figure 1a. (f) HeLa cells
transfected with siNS (N) or siCLIPR-59 (C) were stimulated with TNF-a (100ng/ml) in the presence of CHX (10mg/ml) for the indicated periods. After stimulation, cells were
lysed and immunoprecpitated using anti-Caspase-8-speciﬁc Ab. Precipitated materials were analyzed by IB using the indicated Abs
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Cell Death and DiseaseRIP1 (Figure 3f). These ﬁndings suggest that CLIPR-59 is
involved in and regulates the formation of Complex-II,
containing Caspase-8, FADD and RIP1 in the TNF-a signal
transduction pathway.
CLIPR-59 negatively regulates ubiquitination on RIP1 in
TNF-a signaling. An early event of TNF-a signaling
(o30min after stimulation) entails the formation of
Complex I containing the ligand, its receptor TNFR1, and
associating proteins, including RIP1 and TRADD, resulting in
the ubiquitination of RIP1. Progression to Complex II requires
de-ubiquitination of RIP1.
8,12–14,16 Ectopic expression of
RIP1 induces auto-ubiquitination in mammalian cells.
Therefore, we explored the impact of CLIPR-59 in this
system by using ubiquitin mutant, K63R or K48R, lysine at
the position 63 or 48 is mutated to arginine, respectively. In
the cells expressing wild-type (WT) or K48R ubiquitin,
expression of CLIPR-59 remarkably decreased ubiqui-
tination on RIP1 compared with control cells (Figure 4a).
On the other hands, in the cells expressing K63R ubiquitin,
this effect by the expressed CLIPR-59 was not observed.
These ﬁndings suggested that CLIPR-59 should speciﬁcally
regulate lysine-63-dependent ubiquitination on RIP1.
Regarding to the ubiquitination on RIP1 mediated by TNF-a
stimulation, it is known that in the cells, only a small fraction
of RIP1 recruited into TNFR1 complex, is ubiquitinated.
15
Figure 4 CLIPR-59 regulates the ubiquitination on RIP1 in TNF-a signaling. (a) HEK293T cells were transfected with the expression plasmids for GFP alone ( )o r
GFP-CLIPR-59 (CLIPR-59)(2mg/well) with the combination of the plasmids for FLAG-RIP1 (2mg/well) and HA-ubiquitin WT, K63R or K48R mutant (UB WT, K48R or K63R,
respectively; 0.1mg/well). At 24h after transfection, cells were analyzed as described in Figure 1b. (b) HeLa cells transfected with siCLIPR-59(C) or control siNS(N) were
pretreated with proteasome inhibitor MG132 (21mM) for 10min before stimulation with TNF-a (100ng/ml) or medium for additional 10min. After cell lysing, the cell lysates
weresubjectedtosequentialIPmethodsfordetectingubiquitinationofRIP1associatedwithTNR1asdescribedinMaterialsandMethods.(c)HeLacellsweretransfectedwith
the combination of expression plasmids for the indicated genes. At 24h after the transfection, Caspase-8 activity was assessed as described in Figure 3a. Data are
mean±S.D.; n¼3. (d) HeLa cells were transfected with the expression plasmid for siRNA-resistant RIP1 (RIP1-R) WT or mutated form (K377R),by electropolation, and the
cells were selected by G418 (600mg/ml). These cells were transfected with the indicated combination of siRNAs plus human RIP1-speciﬁc siRNA. At 72h after transfection,
the cells were stimulated with TNF-a (10ng/ml) plus CHX (10mg/ml). At 3h after the stimulation, Caspase-8 activity was assessed as described in Figure 3a. Error bar
means±S.D.; n¼3. *Po0.05 by unpaired t-test. NS, not signiﬁcant. (e) The protein expression level of endogenous RIP1 and siRNA-resistant FLAG-tagged RIP1 WT or
K377R mutant (FLAG-RIP1-R WT or FLAG-RIP1-R K377R, respectively) was assessed by IB using the indicated Ab
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Cell Death and DiseaseTo clarify the role of CLIPR-59 for the ubiquitination on the
receptor associated RIP1, K63- or K48-dependent ubiquiti-
nation states of receptor associated RIP1 by CLIPR-59
knockdown were compared with control siRNA treatment
(Figure 4b). In the control cells (N), K63-dependent
ubiquitinated RIP1 was observed as smear bands with
95–210kDa molecular weight after TNF-a stimulation.
Contrary to this observation, an additional high-molecular
weight smear bands (4210kDa) were observed in CLIPR-59
knock-down cells (C; Figure 4b, upper left panel). In the case
of K48-dependent ubiquitination, the ubiquitinated RIP1 was
observed as smear bands of the same molecular weight
(95–210kDa) in both control and CLIPR-59 knock-down cells
(Figure 4b, upper right panel). These effects by the reduction
of CLIPR-59 expression could not affect on both K63- and
K48-dependent ubiquitination of TRADD involved in the same
receptor complex (Figure 4b, lower left and right panels).
Same effects on K63-linked ubiquitination of RIP1 were
observed in the experiments using the other siRNAs against
CLIPR-59 mRNA (siCLIPR-59 -2 or -3; Supplementary Figure
S4). These ﬁndings suggest that CLIPR-59 regulates K63-
linked ubiquitination of RIP1 in TNF-a signaling.
Recently, it is reported that site-speciﬁc mutation of Lysine
at position 377 on RIP1 prevents its K63-linked ubiquitination
and enhances the formation of RIP1 with Caspase-8 in TNF-a
signaling.
12 Consistent with a role for CLIPR-59 in modulating
ubiquitin-dependent RIP1 signaling, CLIPR-59 expression
enhanced Caspase-8 activation induced by WT RIP1 but not
RIP1 K377R (Figure 4c). More importantly, it is observed that
in HeLa cells expressing mutated RIP1 (RIP1-R K377R),
CLIPR-59 knockdown did not affect the Caspase-8 activation
by TNF-a, unlike in the cells expressing WT (RIP1-R WT)
RIP1 (Figures 4d and e). These ﬁndings suggest that
CLIPR-59negativelyregulatesRIP1ubiquitination topromote
Caspase-8 activation in the context of TNF-a signaling.
Functional association of CLIPR-59 with CYLD in TNF-a
signaling. Ubiquitination of RIP1 is regulated by de-
ubiquitinating enzymes (DUBs), such as CYLD, which is a
K63-speciﬁc DUB, and A20 protein, which is a K63- to K48-
ubiquitination-converting enzyme involved in TNF-a
signaling.
16,19 Because CLIPR-59 has no predicted enzyme
domains,
20 we hypothesized that CLIPR-59 might exert its
function by association with such DUBs. To test this
hypothesis, we ﬁrst determined whether CLIPR-59 could
form protein complexes with CYLD or A20. In co-IP assays
using transfected cells, CLIPR-59 co-IP with CYLD but not
A20 protein (Figure 5a). The carboxy-terminal region of
CLIPR-59, was determined to be essential for its interaction
with CYLD (Supplementary Figures S5A and B) and this
interactive domain is needed for de-ubiquitinating function
of CLIPR-59 (Supplementary Figure S5C, upper panel).
In contrast, C-terminal deletion of CLIPR-59 did not impair its
binding to RIP1 (Supplementary Figure S5C, lower panel).
In addition, CYLD mRNA-speciﬁc siRNA (siCYLD) treat-
ment suppressed de-ubiquitinating activity of CLIPR-59
(Figure 5b). These ﬁndings suggested that CYLD
associates with the de-ubiquitinating function of CLIPR-59.
Regarding the effect of TNF-a stimulation on the formation
of CLIPR-59/CYLD/RIP1 protein complex, it is shown in co-IP
assay that co-precipitated CYLD with CLIPR-59 was
observed more abundantly at late phase (180min) after
TNF-a stimulation than at 0 time or early phase (10min;
Supplementary Figure S5D, upper panel). As it was
also shown in the same condition that TNF-a stimulation
could not affect on the interaction of RIP1 with CLIPR-59
(Supplementary Figure S5D, middle panel), it is suggested
that the formation of CLIPR-59/RIP1/CYLD should be
regulated at the point on the interaction of CLIPR-59 with
CYLD during TNF-a stimulation. To clarify the role of CLIPR-
59 in the formation of RIP1 and CYLD-containing protein
complex, we assessed the effect of siCLIPR-59 on the
association of CYLD with RIP1 in TNF-a-stimulated cells
by co-IP assays using anti-RIP1-speciﬁc Ab. In control
siNS-treated HeLa cells, co-IP of CYLD with RIP1 was
detected after TNF-a plus CHX stimulation. In contrast, in
siCLIPR-59-treated cells, the association of CYLD with RIP1
was reduced (Supplementary Figure S5E). These co-IP
assays provided evidence that CLIPR-59 is needed for the
formation of protein complex containing CYLD and RIP1.
Altogether, these ﬁndings suggest that CLIPR-59 scaffolds
CYLD into the complex containing RIP1 and thus facilitates
de-ubiquitination on RIP1 in TNF-a signaling.
CYLDhasbeenidentiﬁedastheresponsiblegeneforfamilial
cylindromatosis.
21 Previously, it was reported that CYLD
promotes induction of cell death by TNF-a.
22–25 In cell death
assays, overexpression of CYLD signiﬁcantly enhanced
induction of cell death stimulated by TNF-a, but this effect
was abolished in CLIPR-59 knock-down cells (Figure 5c).
Immunoblotting (IB) showed that CLIPR-59 knockdown did not
affect expression of CYLD (Figure 5d). Similar with these
observations, we found that CYLD is also essential for the
enhancement of TNF-a-induced apoptosis caused by CLIPR-
59 overexpression (Supplementary Figure S6A) and that
CLIPR-59 is also needed for the recruitment of CYLD into
Caspase-8 complex (Supplementary Figure S6B). In addition,
siCYLD-treatment reduced the activation of Caspase-8
(Figure 5e) and the formation of Complex-II (Figure 5f)
stimulated by TNF-a, further suggesting that CLIPR-59
modulates CYLD-dependent events of TNFR1 signaling.
In a recent study, it was demonstrated that CYLD is also
essential for the induction of apoptosis and Complex-II
formation by TNF-a in the presence of a Smac mimetic
compounds that induces auto-degradation of endogenous
anti-apoptotic proteins, c-inhibitorofapoptosis(IAP)1/2.
26 We
examined the effect of CLIPR-59 and CYLD knockdown on
the induction of apoptosis by treatment of tumor cell lines with
TNF-a plus Smac mimetics or plus c-IAPs knockdown. In
control siNS-treated HeLa cells, stimulation with TNF-a
robustly activated Caspase-8 in the presence of Smac
mimetic (Compound-3)
27 and also in c-IAP1/2 double knock-
down cells (Supplementary Figure S7 and Figures 5g and h).
Asexpectedfrompriorreports,
28theTNF-a-inducedactivation
of Caspase-8 was reduced by CYLD knockdown (Figure 5h).
Importantly, CLIPR-59 knockdown also prevented the
activation of Caspase-8 by TNF-a in the presence of
Compound-3 or cIAPs knock-down treatment (Figure 5h).
These changes in sensitivity to TNF-a cytoxicity, mediated by
the treatment of siCLIPR-59 or siCYLD, correlated with
differences in RIP1 ubiquitination (Supplementary Figure S8)
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Cell Death and DiseaseThese ﬁndings thus suggest that both CLIPR-59 and CYLD
are essential for activation of Caspase-8 by TNF-a in the
presence of Compound-3.
A cellular model for CLIPR-59-mediated regulation of
sensitivity to TNF-a. Loss of sensitivity to apoptosis
mediated by DRs has a role in the escape of tumors from
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CLIPR-59 with this phenomenon, we ﬁrst examined CLIPR-
59 gene expression in experimental immune-resistant tumor
cells (TC-1 P3 cells) compared with its parental immune-
susceptible cells (TC-1 P0 cells).
29 Quantitative RT-PCR and
IB assays indicated that expression of CLIPR-59 was
markedly reduced in TC-1 P3 cells compared with TC-1 P0
cells (Supplementary Figures S9A and B). TNF-a stimulated
less cell death and less caspase activation in TC-1 P3 cells
compared with TC-1 P0 cells (Supplementary Figures S9C
and D). Transient overexpression of CLIPR-59 in TC-1 P3
cells restored sensitivity to TNF-a (Supplementary Figure
S9E) whereas reduction of CLIPR-59 expression by shRNA
prevented the activation of Caspas-8 by TNF-a stimulation in
TC-1 P0 cells (Supplementary Figure S9F).
Discussion
We have identiﬁed CLIPR-59 as a novel modulator of TNF-a
signaling. CLIPR-59 interacts with the membrane proximal
region of TNFR1 in resting cells. Stimulation of ligand induces
the recruitment of several interacting proteins to TNFR1,
including RIP1 and TRADD to form Complex-I, facilitating the
ubiquitination of RIP1. CLIPR-59 subsequently associates
with CYLD and mediates de-ubiquitination of RIP1, thus
promoting the recruitment of Caspase-8 and FADD to create
Complex-II. In Complex-II, Caspase-8 is activated and
promotes apoptosis (Supplementary Figure S10). In parallel,
we observed that both CLIPR-59 and CYLD were involved in
Complex-I (Supplementary Figure S11) and Complex-II
(Figures 3f and 5f), and K63-linked ubiquitination of RIP1
induced by TNF-a stimulation was signiﬁcantly increased
by CLIPR-59 knock-down treatment (Figure 4b). Thus, we
propose that CLIPR-59 collaborates with CYLD to achieve
de-ubiquitination of RIP1 that thus promote formation of
Complex-II and apoptosis.
We observed that CLIPR-59 dissociates from TNFR1 in
response to receptor aggregation mediated by ligand or
agonistic Ab stimulation, like as other receptor associating
proteins, TRADD and RIP1.
8 In this regard, it has been
suggested that ligand stimulation promotes TNFR1 cleavage
(receptor shedding).
30 Consistent with destruction or shed-
ding of TNFR1 accounting for release of associated cytosolic
proteins, we found that TNFR1 present in cytoplasmic
vesicles at 30min after stimulation (Supplementary Figures
S12 E–G, L, M, R, S, X and Y). As CLIPR-59 did not modulate
TNFR1 expression on the cell surface or ligand-dependent
internalization of TNFR1 (Supplementary Figure S12),
CLIPR-59 probably does not modulate this step.
CLIPR-59 appears to interact directly with RIP1 based on
the results from Y2H assay (Figure 3e). The domains within
CLIPR-59 required for binding RIP1 versus CYLD are
different, as a C-terminal mutant of CLIPR-59 (DC60) still
interacted with RIP1 but not CYLD (Supplementary Figures
S5A–C). It is suggested that interaction of CLIPR-59 with
CYLD but not RIP1 is regulated during TNF-a stimulation
(Supplementary Figure S5D). Moreover, siCLIPR-59 treat-
ment disrupted the formation of protein complex of CYLD with
RIP1(SupplementaryFigureS5E).Weproposethereforethat
CLIPR-59 functions as an adapter that bridges CYLD to RIP1.
Several proteins involved in DR signaling have conserved
domains, such as the DD, which is present in TNFR1, FADD,
TRADD and RIP1, or the death effector domain found in
Caspase-8 and FADD.
7 Both CLIPR-59 and CYLD also have
a conserved domain, the CAP-Gly domain, containing two or
three such domains, respectively.
19,20,23 Here, we show
that the second CAP-Gly of CLIPR-59 is essential for its
interactions with TNFR1 (Figure 1b). Previously, it was
revealed that the ﬁrst and third CAP-Gly domains of CYLD
are responsible for interaction with microtubules and NEMO/
IKKg, respectively.
19,23,31 Although CLIPR-59 binds DR6
17
and TNFR1, CYLD has been demonstrated to associate with
several intracellular signaling molecules, including TNFR1,
EDAR, CD40, TLRs, IL1R, TCR, LMP1 and BCL3.
19,23 Thus,
CYLDmayhavea broaderroleinreceptor-mediated signaling
than CLIPR-59.
RIP1 has multiple roles in regulating cell death signal-
ing.
14,16 Gene disruption of RIP1 prevents the activation of
NF-kB but not the induction of cell death in TNFa-stimulated
murine embryonic ﬁbroblast (MEF) cells.
32 In contrast, RIP1
appears to beessential for induction of apoptosis mediated by
TNF-a in several tumor cell lines, including HeLa and Jurkat
cells.
33,34 Recent reports using RIP1 gene knock-out mice,
also suggest thatRIP1 isdispensable for activating NF-kB but
required fortheinductionofapoptosisinresponse tochemical
antagonists of IAPs, where it has been suggested that the
abolishment of cIAP1 or cIAP2 is needed to unmask RIP1-
induced apoptosis.
35 We assessed the effects of CLIPR-59
knockdown on apoptosis induction by TNF-a in several tumor
cell lines (Supplementary Figure S13), ﬁnding that CLIPR-59
Figure 5 Functional association of CLIPR-59 with CYLD in TNF-a-mediated pro-apoptotic signaling. (a) HEK293T cells were transfected with the indicated combinations
of expression plasmids. At 24h after transfection, cells were lysed and analyzed as described in Figure 1b. (b) HEK293T cells were transfected with the indicated siRNA. At
48h after ﬁrst transfection, cells were reseeded into 6-well culture plate. At 24h after incubation, cells were re-transfected with the expression plasmids for GFP alone ( )o r
GFP-CLIPR-59(2mg/well)withthecombinationoftheplasmidsforFLAG-RIP1(2mg/well)andHA-ubiquitin(UB-WT;0.1mg/well).At24haftersecondtransfection,cellswere
analyzed as described in Figure 1b. (c) HeLa cells were transfected with the indicated siRNA. At 24h after transfection, the cells were reseeded into 12-well culture plate. At
20h after incubation, the cells were transfected with empty or CYLD-expressing plasmids plus GFP-expressing plasmid. At 20h after second transfection, the cells were
stimulated with TNF-a (20ng/ml) in the presence of CHX (10mg/ml). The percentage of the dead cells of transfected GFP-positive cells was assessed as described in
Materials and Methods. Data are mean±S.D.; n¼3. *Po0.05 by unpaired t-test. NS, not signiﬁcant. (d) Expression of CYLD or CLIPR-59 was assessed by IB. (e) HeLa
cellsweretransfectedwiththeindicatedsiRNA.At72haftertransfection,thecellswerestimulatedbytheindicatedreagents.At3hafterstimulation,theactivityofCaspase-8
was measured as described in Figure 3a (error bar means±S.D.; n¼3). (f) HeLa cells transfected with control siRNA (NS) or CYLD gene-speciﬁc (CY) siRNA were
stimulated by TNF-a in the presence of CHX. At various times thereafter, the cells were lysed and analyzed as described in Figure 3f. (h) HeLa cells were transfected with
controlsiNSorsiRNAsagainsttheindicatedgenes(72h)ortreatedwithmediumaloneorsmacmimetic,Compound3(200nM,4h).Aftertreatments,cellswerestimulatedby
TNF-a (10ng/ml, 3h) and Caspase-8 activity was assessed as described in Figure 3a. Effect of these treatments on the protein expression level of cIAP1 or cIAP2 was
assessed as described in Figure 1b (g)
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cancer cells) than A549 (human alveolar basalepithelial cells)
or HT1080 (human ﬁbrosarcoma cells). These ﬁndings
suggest that the role of CLIPR-59 and RIP1 on TNF-a-
mediated pro-apoptotic signaling may be dependent on cell
type and context.
In previous reports,
12,36 it was suggested that post
translational modiﬁcation, such as ubiquitination, of RIP1
switches its function from pro-apoptotic to anti-apoptotic.
Interestingly, constitutive RIP1 ubiquitination is detected in
several tumor cell lines, but was not observed in primary cells
such as MEFs.
13 Interestingly, CLIPR-59 gene expression
is reportedly epigenetically silenced in tumor-conditioned
human umbilical vein endothelial cells.
37 Also, surveying the
Oncomine data set suggests that CLIPR-59 gene expression
is decreased in some tumors compared with normal tissues.
Taken together, these ﬁndings suggest that CLIPR-59
may have a tumor suppressor role, which merits further
investigation.
Materials and Methods
Yeast two-hybrid assay. Yeast strain AH109 was transformed with
combination of expression plasmids for yeast, pGBKT7- or pGADT7-containing
cDNA encoding the indicated gene. Positive yeast clones were selected by
prototrophy for leucine, tryptophan, histidine and adenine.
Immunoprecipitation and IB. Cells were lysed in RIPA buffer (150mM
NaCl, 10mM Tris (pH 7.2), 0.1% SDS, 1.0% Triton X-100, 1% deoxycholate and
5mM EDTA) with serine and threonine phosphatase inhibitor cocktail (Sigma,
St. Louis, MO, USA) and protease inhibitor cocktail (Roche, Heidelberg, Germany).
In some experiments, the lysate was directly analyzed by SDS-PAGE (WCE), while
in others IP with various Abs, was performed. After washing four times with lysis
buffer,theimmunoprecipitatedbeadsweresuspendedinSDS-samplebuffer,boiled
and the eluted material was analyzed by SDS-PAGE. Proteins were transferred to
nitrocellulose membrane (Millipore, Bradford, MA, USA). The membranes were
incubated with the indicated Abs (IB). Visualization of immunoblots was performed
by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA).
siRNA preparation and transfection. All siRNAs used in this study were
obtained from Ambion Inc. (Austin, TX, USA). The target sequences of siRNAs for the
human CLIPR-59 were CLIPR-59; 50-GGACTACGCTTTCACCTTC-30, CLIPR-59-2;
50-GGTCACGCTACCCAACTAT-30 and CLIPR-59-3; 50-CCAACATGAACGCGCTT
CA-30, for human CYLD was 50-GATTGTTACTTCTATCAAA-30.F o rh u m a nc I A P 1
andhumancIAP2, thesequencesweredescribedinpreviously.
38For humanRIP1the
sequences were described previously.
39 Non-speciﬁc siRNA (Silencer Negative
Control #1 siRNA) was used as control (Ambion). For gene-speciﬁc knockdown, HeLa
cells (1 10
6 cells in 10cm tissue culture dish) were transfected with various siRNAs
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the
manufactures. At 24h after transfection, cells were trypsinized and re-seeded into 6-
, 24- or 96-well culture plates. After 24h of culture, cells were analyzed.
Measurement for caspase activity. Cells (1 10
4 cells) were seeded in
96-well white wall culture plates. At 24h after incubation, cells were stimulated and
at3h(forCaspase-8)or4.5h(forCaspase-3/7)afterstimulation,Caspase-3/7or-8
activity was measured by using Caspase Glo-3/7 or -8 reagents (Promega).
Cell viability assay. siRNA-transfected HeLa cells were seeded into 96-well
culture plates. The following day, cells were stimulated with the indicated amount of
TNF-a with CHX (10mg/ml), puromycin (Cayla, Toulouse, France), or zeocin
(Invitrogen). At 6h (for TNF-a with CHX), 24h (for puromycin) or 48h (for zeocin)
after stimulation, cell viability was assessed using the cell counting kit-8 (Dojindo,
Tokyo, Japan).
Immunoprecipitation assay for detecting ubiquitination on
TNFR1-associated RIP1. Detail of IP assay for detecting ubiquitination on
TNFR1-associated RIP1 has been described previously.
15 Brieﬂy, cells were
pretreated with 21mM MG132 proteasome inhibitor for 10min before stimulation
with TNF-a (100ng/ml). These cells were lysed with TNFR1 immunoprcipitation
buffer (20mM Tris-HCl (pH7.5), 150mM NaCl, 1% Triton X-100 and 1mM EDTA)
containing protease inhibitor cocktail and 25mM MG132 at 41C. After centrifugation
for removing debris at 15000r.p.m. at 41C 30min, cell lysate was precleared
with protein G sepharose and then incubated with anti-TNFR1 Ab with protein G
sepharose at 41C overnight. After four times washes with the lysis buffer,
precipitated proteins were eluted in lysis buffer containing 6M urea. Each eluted
sample was diluted 25-fold with lysis buffer for reducing the concentration of urea
and divided two samples. One aliquot was subjected to second IP using anti-K48-
linked ubiquitin chain-speciﬁc Ab (clone Apu2) and the other was subjected to
anti-K63-linked ubiquitin chain-speciﬁc Ab (clone Apu3) with protein G sepharose
for 2h at 41C. After four times washes with lysis buffer, the precipitated materials
were analyzed by western blot method using the indicated Abs.
Cell death assay using ﬂow cytometry. The cells were transfected with
the indicated plasmids. At 24h after transfection, cells were washed two times by
PBS for removing the stimulation-independent dead cells, and then stimulated by
thereagentsinculturemedium.At6haftertreatment,thecellsweretrypsinizedand
resuspended into PBS. Dead cells in each sample were stained with 7-AAD
according to the manufactures.
Fluorescence activities of the cells were detected by Flow cytometer
(BD Biosciences, Heidelberg, Germany). The data were shown as the percentage
of 7-AAD(þ) cells in GFP(þ)-gated cells (at least 10
4 cell counts).
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